Lumitex Inc. seeks patent protection for a phototherapeutic apparatus for treating inflammatory conditions, with a particular focus on treating acute respiratory distress syndrome.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has described heterocyclic derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Researchers at Myrobalan Therapeutics Inc. and Myrobalan Therapeutics Nanjing Co. Ltd. have divulged macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, neurodegeneration, obesity, metabolic diseases, and inflammatory disorders.
Trawsfynydd Therapeutics Inc. has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Valo Health Inc. has disclosed tricyclic phthalazinone compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
When life-saving inhalers sell in Europe at 1.5% to about 8% of their list price in the U.S., they’re bound to attract scrutiny, especially in a time when inequities in prescription drug prices are fueling more and more legislation to reduce U.S. prices.
Vaxess Technologies Inc. seeks patent protection for devices that enable the reliable application of silk fibroin-based microneedle medicament patches used for delivering small molecule drugs, vaccines, peptides, biologics, antibodies, hormones or other materials into or through the skin.
Monte Rosa Therapeutics Inc. has described molecular glue degraders comprising cereblon ligands and a casein kinase 1 Isoform α (CK1α) targeting moiety acting as CK1α degradation inducers reported to be useful for the treatment of cancer.
RSS
